Why wouldn’t these same departments be as as slow at a CRO? -Josh

According to Pharmamodels, “When evaluating the growth of CROs, the statistics show it all. Seven years ago, the biotech and pharmaceutical industry spent $60 billion of which $15 billion was outsourced. This means that CROs accounted for 25 percent of the market seven years ago, a number which has probably increased since then. The partnerships made between sponsors and CROs continue to grow, and there are now numerous networking websites that help connect CROs and Pharmaceutical companies connect”.

This statement indicates that the CRO’s provide efficiency for pre clinical research. This is a major benefit for pharma companies due to their strict deadlines and allocated budgets. CRO’s help reduce the cost for biopharmaceuticals by relieving the overheads spending for the required trials. To answer the question, if CRO’s are rapidly growing or even being outsourced which indicate that their process cannot be slow otherwise companies would not pursue them. Even Forbes magazine show that there is much greater interest in CRO’s than even before due to low costs. A CRO would be providing the exact service and expertise required for the job and since it is an established company, there are professionals doing the work. Therefore, the attitude cannot be lax if the company’s deadline has to be met.